Eris Lifesciences/Natco Pharma partner on semaglutide for India

Eris Lifesciences has announced a partnership with Natco Pharma for the commercialisation of semaglutide in India.

Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Novo Nordisk’s weightloss and diabetes drug Wegovy/ Ozempic, respectively, and a patent on this ingredient is to expire this March in certain markets, including India. Several Indian companies, including Dr Reddy’s Laboratories, Lupin, Cipla and Sun Pharma among others have lined up to bring out their generic versions on the product.

The ₹2,894-crore Eris has built its presence in diabetology and addition of semaglutide will strengthen its portfolio. The collaboration builds on both companies’ strengths - Eris’ commercial and diabetes segment presence, and Natco’s manufacturing and regulatory prowess in complex formulations, a note on the development said.

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026.  Amit Bakshi, Eris Lifesciences Chairman and Managing Director, said, “This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies…Eris is well positioned to drive rapid adoption and enhance patient access in India.”

Published on February 24, 2026